Physician profile
Sarah N Bennett
NPI 1174305692
$3,633.64
in general payments reported to CMS, 2019-2025
22 companies · $2,442 in 2025
The $2,442 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,192 · 2025: $2,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.39 |
| Education | $107.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $647.76 | 2025 | Otezla |
| Abbvie INC. | $609.27 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $285.78 | 2025 | Dupixent |
| Ucb, INC. | $278.21 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $273.82 | 2024-2025 | |
| Janssen Biotech, INC. | $270.98 | 2024-2025 | Tremfya |
| Genzyme Corporation | $226.96 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $207.50 | 2024-2025 | Sotyktu |
| Organon LLC | $161.83 | 2025 | Vtama |
| Dermavant Sciences, INC. | $159.02 | 2024 | Vtama |
| Lilly USA, LLC | $139.62 | 2024-2025 | Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $90.99 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $43.12 | 2024 | |
| Verrica Pharmaceuticals INC. | $40.84 | 2024-2025 | Ycanth |
| Incyte Corporation | $36.34 | 2024 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $34.43 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.65 | 2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $24.59 | 2024 | |
| Kedrion Biopharma, INC. | $23.84 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Galderma Laboratories, L.P. | $17.06 | 2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.98 | 2024 | Cabtreo, Jublia |
| Pfizer INC. | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.